Abbonarsi

Aborted myocardial infarction after primary percutaneous coronary intervention: Magnetic resonance imaging insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial - 24/01/13

Doi : 10.1016/j.ahj.2012.10.028 
Manesh R. Patel, MD a, b, Cynthia M. Westerhout, PhD c, Christopher B. Granger, MD b, Sorin J. Brener, MD d, Yuling Fu, MD c, Hany Siha, MD c, Raymond J. Kim, MD a, Paul W. Armstrong, MD c,
a Duke Cardiovascular Magnetic Resonance Center, Duke University Medical Center, Durham, NC 
b Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 
c University of Alberta, Edmonton, Alberta, Canada 
d New York Methodist Hospital, Brooklyn, NY 

Reprint requests: Paul W. Armstrong, MD, Canadian VIGOUR Centre, University of Alberta, 2-132 Li Ka Shing Centre for Health Research Innovation, Edmonton, AB, Canada T6G 2E1.

Riassunto

Background

Aborted myocardial infarction (AbMI) in patients with ST-elevation MI defined by ST resolution with less than 2-fold elevation in biomarkers has been previously reported. We examined the association among AbMI, other metrics of infarct size, and left ventricular (LV) function defined by cardiac magnetic resonance (CMR).

Methods

A total of 5745 patients with ST-elevation MI enrolled in the APEX-AMI trial, and 73 who were part of the CMR substudy within 3 to 5 days of randomization were evaluated. Core laboratories analyzed electrocardiograms, angiograms, and CMR images.

Results

Aborted MI (peak creatine kinase/creatine kinase MB <2× upper limit of normal) with typical evolutionary electrocardiogram changes was observed in 11% (437/3938) overall and in 19% (14/73) of patients within the CMR study. Patients with AbMI were older (62 vs 60 years, P = .003) and tended to achieve complete STE-resolution post–percutaneous coronary intervention (≥70% resolution: 64% vs 32%; P = .076) compared with patients with MI. Cardiac magnetic resonance revealed that patients with AbMI had a smaller infarct size (4.7% vs 14.9% LV, P < .001), less “no reflow” (0.9% vs 1.7% LV, P = .017), enhanced LV function (ejection fraction 54.4% vs 46.5%, P = .064), smaller LV end-systolic volumes (46.5 mL vs 67.2 mL, P = .009), and less transmurality (21.4% vs 50.9% with at least 1 segment with >75% wall thickness, P = .046) when compared with patients with MI.

Conclusions

Patients with AbMI had smaller subendocardial infarcts with enhanced LV size and function. Cardiac magnetic resonance provides corroborative evidence of AbMI and insights into its pathophysiology, specifically rapid successful reperfusion leading to limitation of the “wavefront” of infarct to the subendocardium.

Il testo completo di questo articolo è disponibile in PDF.

Mappa


 George A. Beller, MD, served as guest editor for this article.
 Randomized controlled trial registration no. NCT00091637.


© 2013  Mosby, Inc. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 165 - N° 2

P. 226-233 - Febbraio 2013 Ritorno al numero
Articolo precedente Articolo precedente
  • Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: Insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial
  • Andrew P. Ambrosy, Muthiah Vaduganathan, Robert J. Mentz, Stephen J. Greene, Haris Suba?ius, Marvin A. Konstam, Aldo P. Maggioni, Karl Swedberg, Mihai Gheorghiade
| Articolo seguente Articolo seguente
  • Targeted anti-inflammatory systemic therapy for restenosis: The Biorest Liposomal Alendronate with Stenting sTudy (BLAST)—a double blind, randomized clinical trial
  • Shmuel Banai, Ariel Finkelstein, Yaron Almagor, Abid Assali, Yonathan Hasin, Uri Rosenschein, Patricia Apruzzese, Alexandra J. Lansky, Teruyoshi Kume, Elazer R. Edelman

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2025 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.